Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes — [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience — do we need [18F]FDG PET/CT for qualification to PRRT?
INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). The aim of the study was the evaluation of the role of [¹⁸F]FDG PET/CT in predicting response, progression-free sur...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Via Medica
2020-06-01
|
| Серія: | Endokrynologia Polska |
| Предмети: | |
| Онлайн доступ: | https://journals.viamedica.pl/endokrynologia_polska/article/view/67499 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|